Aug 2026· Blood cell therapy· Vol 9, pp. 131 - 136· 0 citations· 20 references
Medicine
TL;DR
A 47-year-old man with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who underwent haploidentical sibling peripheral blood HSCT is reported, highlighting an uncommon transition from donor-type marrow failure to autologous recovery and underscores the importance of bone marrow-based chimerism monitoring in cytopenic post-transplant patients.
Abstract
Secondary graft failure after initial donor engraftment is a rare complication of allogeneic hematopoietic stem cell transplantation (HSCT). We report a 47-year-old man with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL) who underwent haploidentical sibling peripheral blood HSCT after second complete remission. Neutrophil engraftment occurred by Day +14 with platelet engraftment by Day +18. Beginning Day +22, recurrent fever with progressive cytopenias developed. Day +30 peripheral blood short tandem repeat (STR) analysis showed complete donor chimerism; however, cytomegalovirus (CMV) DNAemia increased to 3,736 IU/mL, prompting therapeutic valganciclovir. Bone marrow biopsy on Day +37 showed hypocellular marrow without residual disease, although bone marrow X/Y fluorescence in situ hybridization (FISH) demonstrated 100% XY signals despite a female donor, indicating graft loss. Septic shock developed on Day +48. Management included growth factors, temporary tacrolimus withdrawal, antibiotics, granulocyte infusions, and a stem cell boost on Day +62. Repeat peripheral blood chimerism by Day +95 showed complete recipient genotype, confirming secondary graft failure with autologous reconstitution. Follow-up through Day +183 confirmed sustained autologous hematopoiesis with no relapse or graft-versus-host disease (GVHD). This case highlights an uncommon transition from donor-type marrow failure to autologous recovery and underscores the importance of bone marrow-based chimerism monitoring in cytopenic post-transplant patients.
A second allo-HSCT in pediatric patients with GF complicated by MAS/sHLH demonstrates acceptable engraftment and survival outcomes, remaining the only available option for long-term disease control.
P. Kozhokar, O. Yudintseva, O. Paina et al.· Pediatric Hematology/Oncolog...· 0 citations
BACKGROUND
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent...
Carmen Junk, Sebastian U. Michaelis, M. Döring et al.· Pediatric Blood & Cancer· 0 citations
A pediatric patient with severe aplastic anemia who developed umbilical cord blood–derived early T-cell precursor acute lymphoblastic leukemia 2 years and 5 months after receiving an allo-HSCT is reported, highlighting the refractory nature of post-transplant donor cell leukemia.
Zhi Chen, Ming Sun, Zhuo Wang et al.· Frontiers in Pediatrics· 0 citations
Two solid organ transplant recipients treated with non-myeloablative conditioning followed by naïve T-cell-depleted hematopoietic stem cell transplantation and donor memory T-cell infusions use mixed lymphocyte reactions with TCRβ sequencing to track donor-reactive T-cell clonotypes to support minimization of immunosup...
A. Pérez-Martínez, C. Aguirre-Portolés, C. Mestre-Durán et al.· Communications Medicine· 0 citations
This case suggests that a multidisciplinary treatment strategy incorporating TBF conditioning may improve relapse-free survival in patients with BP-MPN.
Shintaro Abe, Shintaro Izumi, Shokichi Tsukamoto et al.· [Rinsho ketsueki] The Japane...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.